HU0004747D0 - - Google Patents

Info

Publication number
HU0004747D0
HU0004747D0 HU0004747A HUP0004747A HU0004747D0 HU 0004747 D0 HU0004747 D0 HU 0004747D0 HU 0004747 A HU0004747 A HU 0004747A HU P0004747 A HUP0004747 A HU P0004747A HU 0004747 D0 HU0004747 D0 HU 0004747D0
Authority
HU
Hungary
Application number
HU0004747A
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of HU0004747D0 publication Critical patent/HU0004747D0/hu
Publication of HUP0004747A2 publication Critical patent/HUP0004747A2/hu
Publication of HUP0004747A3 publication Critical patent/HUP0004747A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU0004747A 1999-11-30 2000-11-29 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline derivatives and process for their preparation HUP0004747A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16796799P 1999-11-30 1999-11-30

Publications (3)

Publication Number Publication Date
HU0004747D0 true HU0004747D0 (hu) 2001-02-28
HUP0004747A2 HUP0004747A2 (hu) 2001-10-28
HUP0004747A3 HUP0004747A3 (en) 2002-12-28

Family

ID=22609556

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0004747A HUP0004747A3 (en) 1999-11-30 2000-11-29 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinoline derivatives and process for their preparation

Country Status (45)

Country Link
US (1) US6313142B1 (hu)
EP (1) EP1125929B1 (hu)
JP (1) JP3579345B2 (hu)
KR (1) KR100408177B1 (hu)
CN (1) CN1173953C (hu)
AP (1) AP2000002011A0 (hu)
AR (1) AR029775A1 (hu)
AT (1) ATE315028T1 (hu)
AU (1) AU784694B2 (hu)
BG (1) BG105009A (hu)
BR (1) BR0005636A (hu)
CA (1) CA2327029C (hu)
CO (1) CO5261552A1 (hu)
CY (1) CY1104989T1 (hu)
CZ (1) CZ20004407A3 (hu)
DE (1) DE60025317T2 (hu)
DK (1) DK1125929T3 (hu)
DZ (1) DZ3079A1 (hu)
EA (1) EA003668B1 (hu)
EE (1) EE200000659A (hu)
ES (1) ES2254109T3 (hu)
GE (1) GEP20022798B (hu)
GT (1) GT200000190A (hu)
HK (1) HK1038007A1 (hu)
HN (1) HN2000000203A (hu)
HR (1) HRP20000804A2 (hu)
HU (1) HUP0004747A3 (hu)
ID (1) ID28489A (hu)
IL (1) IL139849A (hu)
IS (1) IS5715A (hu)
MA (1) MA25223A1 (hu)
NO (1) NO20006039L (hu)
NZ (1) NZ508509A (hu)
OA (1) OA11494A (hu)
PA (1) PA8503801A1 (hu)
PE (1) PE20010913A1 (hu)
PL (1) PL344208A1 (hu)
SG (1) SG102603A1 (hu)
SK (1) SK17792000A3 (hu)
TN (1) TNSN00230A1 (hu)
TW (1) TW591016B (hu)
UA (1) UA65615C2 (hu)
UY (1) UY26451A1 (hu)
YU (1) YU71500A (hu)
ZA (1) ZA200006947B (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
US7202247B2 (en) 2001-12-19 2007-04-10 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
EP1465854A4 (en) * 2001-12-19 2005-06-08 Atherogenics Inc CHALCONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES
JP4339702B2 (ja) * 2002-04-11 2009-10-07 ロアー ホールディング エルエルシー Ｃｅｔｐ活性及び心臓病治療（剤）の効力（有効性）の生体外測定方法
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
AU2003277285B2 (en) * 2002-10-04 2007-12-13 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7223870B2 (en) * 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
WO2004056727A2 (en) * 2002-12-19 2004-07-08 Atherogenics, Inc. Process of making chalcone derivatives
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
EP1578415B1 (en) 2002-12-20 2008-09-10 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
EP1601655A2 (en) * 2003-03-04 2005-12-07 Takasago International Corporation Method for producing optically active amines
KR20050110017A (ko) * 2003-03-17 2005-11-22 니뽄 다바코 산교 가부시키가이샤 Ｓ-'２-(''１-(２-에틸부틸)시클로헥실!카르보닐!아미노)페닐!-２-메틸프로판티오에이트의 경구 생체이용율을증가시키는 방법
US20040225018A1 (en) * 2003-03-17 2004-11-11 Japan Tobacco Inc. Pharmaceutical compositions of CETP inhibitors
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
SI1670768T1 (sl) * 2003-10-08 2010-01-29 Lilly Co Eli Spojine in metode za zdravljenje dislipidemije
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
KR20070041452A (ko) * 2004-06-24 2007-04-18 일라이 릴리 앤드 캄파니 이상지혈증 치료를 위한 화합물 및 방법
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
WO2006069162A1 (en) * 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
AU2006216713A1 (en) * 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
UY30244A1 (es) 2006-03-30 2007-11-30 Tanabe Seiyaku Co Un proceso para preparar derivados de tetrahidroquinolina
TW200901959A (en) 2007-03-09 2009-01-16 Indigene Pharmaceuticals Inc Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
CN101429160B (zh) * 2007-11-06 2011-10-19 上海药明康德新药开发有限公司 一种1-r-4-氨基-1,2,3,4-四氢喹啉的合成方法
AR077208A1 (es) * 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7870M (hu) * 1968-11-08 1970-04-27
US3971789A (en) 1972-10-21 1976-07-27 John Wyeth & Brother Limited O-(4-Quinolylamino)benzamides
GB8432091D0 (en) 1984-12-19 1985-01-30 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US4839368A (en) 1986-05-02 1989-06-13 Mochida Pharmaceutical Co., Ltd. 1-acyl-2,3-dihydro-4(1H)-quinolinone-4-oxime derivatives
GB8804444D0 (en) 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
US5231102A (en) 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.

Also Published As

Publication number Publication date
ZA200006947B (en) 2002-05-27
DK1125929T3 (da) 2006-04-03
TNSN00230A1 (fr) 2005-11-10
IL139849A (en) 2006-10-31
SK17792000A3 (sk) 2002-10-08
NZ508509A (en) 2001-06-29
GEP20022798B (en) 2002-09-25
MA25223A1 (fr) 2001-07-02
BG105009A (en) 2001-11-30
UA65615C2 (uk) 2004-04-15
TW591016B (en) 2004-06-11
UY26451A1 (es) 2001-06-29
GT200000190A (es) 2002-04-27
CA2327029C (en) 2005-08-09
ES2254109T3 (es) 2006-06-16
SG102603A1 (en) 2004-03-26
NO20006039D0 (no) 2000-11-29
BR0005636A (pt) 2001-07-17
PA8503801A1 (es) 2002-07-30
HUP0004747A2 (hu) 2001-10-28
EA200001129A3 (ru) 2001-10-22
ID28489A (id) 2001-05-31
KR20010052012A (ko) 2001-06-25
JP3579345B2 (ja) 2004-10-20
PL344208A1 (en) 2001-06-04
HK1038007A1 (en) 2002-03-01
OA11494A (en) 2004-05-07
YU71500A (sh) 2003-02-28
AU7178900A (en) 2001-05-31
CN1302800A (zh) 2001-07-11
EE200000659A (et) 2001-08-15
CY1104989T1 (el) 2010-03-03
EA003668B1 (ru) 2003-08-28
HN2000000203A (es) 2001-06-13
HRP20000804A2 (en) 2001-06-30
NO20006039L (no) 2001-05-31
KR100408177B1 (ko) 2003-12-01
CO5261552A1 (es) 2003-03-31
AR029775A1 (es) 2003-07-16
PE20010913A1 (es) 2001-09-10
HUP0004747A3 (en) 2002-12-28
DE60025317D1 (de) 2006-03-30
AU784694B2 (en) 2006-06-01
JP2001163859A (ja) 2001-06-19
EP1125929B1 (en) 2006-01-04
IS5715A (is) 2001-05-31
EP1125929A1 (en) 2001-08-22
ATE315028T1 (de) 2006-02-15
US6313142B1 (en) 2001-11-06
DE60025317T2 (de) 2006-08-03
IL139849A0 (en) 2002-02-10
CZ20004407A3 (cs) 2002-06-12
AP2000002011A0 (en) 2000-12-31
DZ3079A1 (fr) 2004-10-24
CA2327029A1 (en) 2001-05-30
EA200001129A2 (ru) 2001-06-25
CN1173953C (zh) 2004-11-03

Similar Documents

Publication Publication Date Title
BE2018C020I2 (hu)
BE2015C057I2 (hu)
BE2016C007I2 (hu)
BE2012C036I2 (hu)
BE2011C004I2 (hu)
BE2010C011I2 (hu)
BE1025464I2 (hu)
BE2008C046I2 (hu)
JP2002526326A5 (hu)
JP2002529806A5 (hu)
BRPI0017527B8 (hu)
JP2002529678A5 (hu)
JP2002523192A5 (hu)
BE2008C047I2 (hu)
BRPI0001672A2 (hu)
BRPI0001542A2 (hu)
JP2002534669A5 (hu)
HU0004747D0 (hu)
JP2002505538A5 (hu)
BRPI0012675B8 (hu)
BRPI0017522A2 (hu)
JP2002527956A5 (hu)
BRMU7902607U2 (hu)
HU0004189D0 (hu)
IN185800B (hu)

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees